Skip to main content
. 2022 Jun 2;11(4):1551–1561. doi: 10.1007/s40123-022-00530-x

Fig. 2.

Fig. 2

Goblet cell a area change, b perimeter change from pre to post treatment (both eyes; primary efficacy endpoints), and c image for OC-01 VNS. Inserts present a mean goblet cell area pre treatment and b mean goblet cell perimeter pre treatment. OC-01 VNS OC-01 (varenicline solution) nasal spray, SD standard deviation